Document is current

Article History

Received: 3 October 2023

Accepted: 24 November 2023

First Online: 10 January 2024

Declarations

:

: Jean-François Korobelnik has received consulting fees from AbbVie, Apellis, Bayer, Janssen, Nano Retina, Roche, Théa Pharmaceuticals, and Carl Zeiss Meditec AG; and is a member of data safety monitoring boards or advisory boards for Alexion, Novo Nordisk, and Oxular. Varun Chaudhary has received grants from Allergan Inc., Bayer Healthcare, Novartis, and Roche; consulting fees from Allergan-AbbVie, Apellis, Bayer, Care Zeiss Meditec AG, Janssen, Nano Retina, Roche, and Théa Pharmaceuticals; and is a scientific advisor for Alcon Laboratories, Bayer Healthcare, Novartis, and Roche. Paul Mitchell has received consulting fees from Allergan, Apellis, Bayer, Novartis, and Roche; lecture honoraria from Bayer; support for attending meetings and/or travel from Bayer and Roche; and is a member of data safety monitoring boards or advisory boards for Apellis and Bayer. Se Woong Kang has received personal fees and non-financial support from Bayer Korea. Ramin Tadayoni has received consulting fees from Alcon Laboratories, Allergan, Bausch + Lomb, Novartis, Roche, Genentech, and ZEISS; and is a board member for Alcon Laboratories, Alimera Sciences, Allergan, Bausch + Lomb, Bayer, FCI, and Novartis. Helmut Allmeier and Xin Zhang are employees of Bayer Consumer Care AG. Tobias Machewitz and JinKyung Lee are employees of Bayer AG. Clare Bailey has received honoraria from Alimera Sciences, Apellis, Bayer, Boehringer Ingelheim, Janssen, Novartis, and Roche; and is a member of advisory boards for Alimera Sciences, Apellis, Bayer, Boehringer Ingelheim, Janssen, Novartis, and Roche.

: The XTEND study was conducted in accordance with the Helsinki Declaration of 1964 and the applicable EMA guidelines and local laws and regulations in each country. The recommendations of the European Federation of Pharmaceutical Industries and Associations, European Network of Centers for Pharmacoepidemiology and Pharmacovigilance, Good Pharmacovigilance Practices (GVP module VI), and International Council for Harmonization Guideline E3: Good Clinical Practice were also followed wherever possible. In all countries, where required, the protocol and any amendments were reviewed and approved by each study site’s IEC or IRB before and during the study. The full list of Ethics Approval Boards that approved the study is provided in ESM Table 1. All patients gave informed consent to participate in the study.